Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs

References

• Abu-Hamdah R, Rabiee A, Meneilly GS, et al. (2009). Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 94:1843–52
   PubMed Web of Science ®Google Scholar
• Angeli FS, Shannon RP. (2013). Incretin based therapies: can we achieve glycemic control and cardioprotection? J Endocrinol In Press
   Web of Science ®Google Scholar
• Ban K, Hui S, Drucker DJ, Husain M. (2009). Cardiovascular consequences of drugs used in the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 3:245–59
   PubMed Web of Science ®Google Scholar
• Ban K, Noyan-Ashraf MH, Hoefer J, et al. (2008). Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor-dependent and independent pathways. Circulation 117:2340–50
   PubMed Web of Science ®Google Scholar
• Bhashyam S, Fields AV, Patterson B, et al. (2010). Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 3:512–21
   PubMed Web of Science ®Google Scholar
• Cernea S, Raz I. (2011). Therapy in the early stage: incretins. Diabetes Care 34(Suppl 2):S264–71
   PubMed Web of Science ®Google Scholar
• Chappell DL, Lee AY, Castro-Perez J, et al. (2014). An ultrasensitive method for the quantitation of active and inactive GLP-1 in human plasma via immunoaffinity LC-MS/MS. Bioanalysis 6:33–42
   PubMed Web of Science ®Google Scholar
• Davis B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. (1995a). Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocr Metab 80:952–7
   PubMed Web of Science ®Google Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, et al. (1995b). Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126–31
   PubMed Web of Science ®Google Scholar
• Edwards C. (2013). Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes. Br J Hosp Med (Lond) 74:198–201
   PubMed Web of Science ®Google Scholar
• Elahi D, Egan JM, Shannon RP, et al. (2008). Glucagon-like peptide-1 (9-36) amide, cleavage product of glucagon-like peptide-1 (7-36) is a glucoregulatory peptide. Obesity 16:1501–9
   PubMed Web of Science ®Google Scholar
• Fineman MS, Cirincione BB, Maggs D, Diamant M. (2012). GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 14:675–88
   PubMed Web of Science ®Google Scholar
• Hansen L, Deacon CF, Orskov C, Holst JJ. (1999). Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356–63
   PubMed Web of Science ®Google Scholar
• Holst JJ. (2007). The physiology of glucagon-like peptide 1. Physiol Rev 87:1409–39
   PubMed Web of Science ®Google Scholar
• Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–79
   PubMed Web of Science ®Google Scholar
• Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. (1995). Characterization of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149–56
   PubMed Web of Science ®Google Scholar
• Medzihradszky KF. (2005). Peptide sequence analysis. Methods Enzymol 402:209–44
   PubMed Web of Science ®Google Scholar
• Mentlein R. (1999). Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regul Pept 85:9–24
   PubMed Web of Science ®Google Scholar
• Mundil D, Cameron-Vendrig A, Husain M. (2012). GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res 9:95–108
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Elahi D, Hentosz T, et al. (2004). Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110:955–61
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Elahi D, Shen YT, Shannon RP. (2005). Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289:H2401–8
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58
   PubMed Web of Science ®Google Scholar
• Pridal L, Deacon CF, Kirk O, et al. (1996). Glucagon-like peptide peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma. Eur J Drug Metab Pharmacokinet 21:51–9
   PubMed Web of Science ®Google Scholar
• Sharma R, McDonald TS, Eng H, et al. (2013). In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. Drug Metab Dispos 41:2148–57
   PubMed Web of Science ®Google Scholar
• Thorens B. (1992). Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89:8641–5
   PubMed Web of Science ®Google Scholar
• Tomas E, Habener JF. (2010). Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 21:59–67
   PubMed Web of Science ®Google Scholar
• Tomas E, Stanojevic V, Habener JF. (2010). GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res 42:657–62
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. (2012). Cardiovascular biology of the incretin system. Endocr Rev 33:187–215
   PubMed Web of Science ®Google Scholar
• Wysocki VH, Resing KA, Zhang Q, Cheng G. (2005). Mass spectrometry of peptides and proteins. Methods 35:211–22
   PubMed Web of Science ®Google Scholar